Roche Announces RMB 2.04 Billion Investment to Build New Biopharmaceutical Manufacturing Facility in Shanghai

On May 8, Roche Pharmaceuticals China announced an investment of 2.04 billion yuan to build a new biopharmaceutical production base in Shanghai. The investment project launch ceremony was held on the same day. The company stated that this increased investment aims to comprehensively strengthen the end-to-end complete pharmaceutical value chain by enhancing the company’s supply chain and localized production layout in China. The project is located in the Zhangjiang High-Tech Park, covering an area of approximately 53 mu, with a construction area of about 25,000 square meters. The project is expected to be officially completed in 2029 and begin operations in 2031. The base will be used for the localized production of Rocevita® (Faricimab Injection) to continuously meet the needs of Chinese patients for innovative therapies. (Shanghai Observer)